Modality
Bispecific Ab
MOA
PD-L1i
Target
GLP-1R
Pathway
Autophagy
CTCLHeart FailureSMA
Development Pipeline
Preclinical
~Jan 2016
→ ~Apr 2017
Phase 1
~Jul 2017
→ ~Oct 2018
Phase 2
~Jan 2019
→ ~Apr 2020
Phase 3
~Jul 2020
→ ~Oct 2021
NDA/BLA
~Jan 2022
→ ~Apr 2023
Approved
Jul 2023
→ Jul 2031
ApprovedCurrent
NCT08681394
62 pts·Heart Failure
2023-07→2031-07·Not yet recruiting
62 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2031-07-105.3y awayPh3 Readout· Heart Failure
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
Approved
Not yet…
Catalysts
Ph3 Readout
2031-07-10 · 5.3y away
Heart Failure
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08681394 | Approved | Heart Failure | Not yet recr... | 62 | eGFR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| PFE-2191 | Pfizer | NDA/BLA | GLP-1R | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| Tirzepatide | Eli Lilly | Approved | GLP-1R | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Mavuglumide | Bayer | Approved | GLP-1R |